Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study.
Kumar P, Clarke AE, Jonsson-Oldenbüttel C, Deltoro MG, Di Giambenedetto S, Brites C, Hocqueloux L, Lu PL, Oyee J, Oglesby A, Wynne B, Jones B, Evitt LA, Fox D, Kisare M, Priest J.
Kumar P, et al. Among authors: fox d.
AIDS Behav. 2024 Sep 3. doi: 10.1007/s10461-024-04479-9. Online ahead of print.
AIDS Behav. 2024.
PMID: 39225890